Therapeutic Response

RET oncogenic variants status confers therapeutic sensitivity to Selpercatinib in patients with Medullary Thyroid Cancer.

Statements

Source and description
Retevmo (selpercatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.